Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Arcutis Biotherapeutics is a commercial-stage dermatology company focused on topical immunomodulators for inflammatory skin diseases. The company markets ZORYVE (roflumilast) cream 0.3% for plaque psoriasis and seborrheic dermatitis, representing the first FDA-approved topical PDE4 inhibitor. With 90%+ gross margins and 230% revenue growth, Arcutis is in early commercialization phase, burning cash to build market share in the $8B+ US topical dermatology market.
Arcutis generates revenue through branded prescription dermatology products sold via specialty pharmacy and retail channels. The company employs a targeted dermatology sales force calling on approximately 8,000-10,000 high-prescribing dermatologists. Pricing power derives from differentiated mechanism of action (PDE4 inhibition), favorable safety profile versus systemic therapies, and managed care coverage. Gross margins exceed 90% due to low manufacturing costs for topical formulations, with profitability dependent on achieving commercial scale to absorb $130M+ annual operating expenses. The company benefits from high switching costs once physicians adopt the product into treatment algorithms and patients achieve therapeutic response.
ZORYVE prescription volume trends (TRx and NRx weekly data from IQVIA/Symphony)
Managed care coverage wins and formulary positioning (percentage of covered lives with favorable access)
Clinical trial readouts for pipeline assets (topical JAK inhibitors ARQ-252 and ARQ-255)
Quarterly revenue beats/misses versus Street estimates and guidance updates
Cash runway extensions through financing or partnership deals
Generic competition risk beginning 2035-2037 when ZORYVE composition-of-matter patents expire, though formulation patents extend protection
Shift toward value-based care and biosimilar adoption in dermatology could pressure pricing power and formulary access over 5-10 year horizon
Regulatory risk from potential FDA safety reviews of PDE4 inhibitor class, particularly given psychiatric adverse event monitoring requirements
Established topical corticosteroids and vitamin D analogs offer 90%+ lower cost alternatives, requiring continuous physician education on differentiated benefits
Amgen's OTEZLA (oral PDE4 inhibitor) and emerging topical JAK inhibitors from Incyte/Pfizer create mechanism-of-action competition
Large dermatology players (LEO Pharma, Bausch Health, Galderma) possess superior sales force scale and managed care leverage
Cash burn of $25-30M per quarter creates financing risk if revenue growth disappoints, potentially requiring dilutive equity raise in 2026-2027
Convertible debt maturity in 2028 ($287M principal) requires refinancing or conversion, creating overhang
Limited financial flexibility to pursue M&A or in-license additional assets while burning cash to support ZORYVE launch
low - Prescription dermatology products demonstrate relative recession resilience as chronic inflammatory skin conditions require ongoing treatment regardless of economic conditions. However, high out-of-pocket costs for branded dermatology drugs ($50-150 copays) create modest sensitivity to consumer discretionary spending. Patient abandonment rates may increase 5-10% during economic downturns when households prioritize spending. The company's growth is driven primarily by market share capture and new patient starts rather than GDP-linked demand.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, with biotech sector multiples contracting 20-30% when 10-year yields rise 100bps; (2) Increased cost of capital for future financing needs, though current $115M+ cash position provides 12-18 month runway. The company's negative cash flow profile makes it more sensitive to rate-driven multiple compression than profitable peers.
Minimal direct credit exposure. The company maintains investment-grade short-term investments and has limited accounts receivable concentration risk across specialty pharmacy and wholesaler channels. Debt-to-equity of 0.72x represents manageable convertible note obligations. Indirect credit sensitivity exists through managed care payer mix, as Medicaid expansion/contraction affects patient access and reimbursement rates.
growth - The stock attracts growth-oriented biotech investors focused on commercial-stage dermatology opportunities with blockbuster potential. The 230% revenue growth, 90%+ gross margins, and 113% one-year return appeal to momentum investors willing to accept negative cash flow for market share capture. High institutional ownership from healthcare-focused funds (RTW Investments, Perceptive Advisors) indicates sophisticated biotech specialists. Not suitable for value or income investors given negative earnings, no dividend, and 10.3x price-to-sales valuation.
high - Biotech stocks in early commercialization exhibit 40-60% annualized volatility driven by binary clinical/regulatory events, quarterly earnings surprises, and sector rotation. The stock's 57% six-month return demonstrates momentum characteristics. Small-cap biotech beta typically ranges 1.5-2.0x versus broader market. Prescription data releases, managed care decisions, and clinical trial readouts create event-driven volatility spikes of 15-25% in single sessions.
